(2)
Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancers
Latest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim s position in the cancer vaccine and T-cell engager spaces
Agreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio s EDAPT platform and Dark Antigen discovery work and supports ongoing cell therapy based therapeutic approach
Boehringer Ingelheim and Enara Bio, today announced that they have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio s Dark Antigen discovery platform. This new collaboration combines Boehringer Ingelheim s approach to tackle cancer through pairing leading science with innovative immune-oncology platforms, such as oncolytic viruses and cancer vaccines, with Enara Bio s expertise in cancer antigen identification. The aim is to provide poten